Bionano's Q3 Test: Can Flow Cell Supply And Thin Cash Keep Pace With Demand?

Bionano Genomics heads into its third-quarter report with an unusual problem for a small diagnostics toolmaker: customers appear to want more of its optical genome mapping consumables than it can currently make. That is a good problem to have, but only if the company can manufacture its way out of it before a shrinking cash balance forces harder choices. The report due after the close on November 10 should show whether last quarter's acceleration was the start of a durable clinical adoption curve or a strong quarter that the factory and the balance sheet cannot sustain.

Wall Street expects a loss of $0.56 per share on revenue of about $8.4 million. That revenue figure sits squarely at the midpoint of management's $8.2 million to $8.6 million guidance and represents roughly 14% growth from the year-ago quarter, a solid if unspectacular pace after the 21% jump posted in the second quarter. The projected loss would mark a sharp improvement from the $1.59 per-share loss a year earlier and a modest step forward from last quarter's $0.64. With the Street parked at the middle of the range, the bar is neither aggressive nor generous, so the details beneath the headline numbers will matter more than a small beat or miss.

The most important detail is flow cells. Bionano sold a record 9,219 last quarter, up 27% from a year earlier and accelerating from 17% growth in the first quarter, while consumable revenue climbed 30%. Management tied that momentum to Category 1 CPT reimbursement finally converting into clinical use, with European clinical customers now driving a majority of revenue. Yet the same call made clear that manufacturing capacity is the ceiling, with backlog not expected to clear until mid-to-late in the fourth quarter. That explains why the full-year high end stayed at $33 million even as the low end rose to $31 million, and why the third-quarter guide implies only flat-to-modest sequential growth. Another sequential gain in flow cell volume would validate the capacity ramp; a stall would suggest supply, not demand, is defining the story for longer than hoped. Management also flagged several large orders that could slip, so timing noise is a real risk.

Margins are the second pillar. Gross margin reached a record 53%, up from 43% just two quarters earlier, reflecting a richer consumables mix. Holding near that level would argue the improvement is structural. Software, meanwhile, remains the soft spot after falling 16% on deployment delays, and a rebound there would ease concerns that this line is eroding rather than merely lumpy. Investors should also look for an update on the Ionic-OGM sample prep interface slated for a fourth-quarter launch.

The balance sheet may ultimately overshadow everything. Cash fell to $10.4 million in the second quarter from $24.7 million, a period that also saw the convertible debt fully retired, and management said runway extends only into at least the first quarter of 2027. The third-quarter cash figure, burn rate and any financing commentary will be scrutinized, along with progress on the search for a permanent CEO.

Sentiment has softened its bearish edge, moving from 8.0% bearish before the last report to 2.3% bearish now, and the stock has held flat while the S&P 500 slipped 2.9%. That relative resilience masks a round trip, though: shares spiked as high as $2.23 after the last report and now trade at $1.16, near the $1.10 low of that range and below the 200-day average of $1.24. The market appears to believe the demand story but doubt the funding. The central question is whether Bionano can show rising flow cell output, steady margins and a credible cash path at the same time, because demand alone will not carry the narrative if the company cannot afford to meet it.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.